Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Monday 07 June, 2021

Omega Diagnostics Gp

Progress update

RNS Number : 9534A
Omega Diagnostics Group PLC
07 June 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Progress update

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, provides the following update on its UK Government manufacturing contract.

 

Update on UK Government manufacturing contract

The Company remains in regular dialogue with the Department of Health and Social Care ("DHSC") to provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose. Omega is still waiting for confirmation on which test it will be required to manufacture.  Omega is not in control of this process and this is taking longer than originally expected but the Company will provide a further update once a test is confirmed. The ability to supply tests that are produced within the UK remains a key priority for the DHSC and to that end the DHSC have facilitated initial commercial discussions between Omega and potential partner companies with lateral flow antigen tests to potentially provide UK manufacturing services.

 

In the meantime, Omega is currently supporting the Government with additional cassetting and pouching services for other COVID-19 antigen lateral flow tests that are being deployed in the UK.

 

The Company can also confirm that as part of the UK Government manufacturing contract announced on 11 February 2021 it has received cash Preproduction Payments totalling £2.5m (excluding VAT), with £2.0m of this cash payment received after the year ended 31 March 2021. It is expected that an amount per test, sufficient to recover the Preproduction Payment, will be deducted until such time as the funds have been repaid.

 

Colin King, CEO of Omega, commented: 

"Whilst confirmation from the DHSC of which test to produce has taken longer than we had expected, we are confident that we have the capacity to produce significant volumes of tests once we receive the requisite confirmation from DHSC. Obviously as soon as this is confirmed we will update shareholders."

 

  Contacts: 

 

Omega Diagnostics Group PLC

www.omegadiagnostics.com

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director




finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)


Alice Lane (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDQLFBFQLLBBF

a d v e r t i s e m e n t